Propanc Biopharma, Inc. announced the successful production of synthetic recombinant proenzymes trypsinogen and chymotrypsinogen through the Proenzyme Optimization Project 1 (POP1) joint research and drug discovery program.
The project was conducted in collaboration with the Universities of Jaén and Granada, Spain. The synthetic development of these proenzymes aims to create a backup clinical compound to the Company's lead product candidate, PRP, for targeting metastatic cancer from solid tumors.
The research findings showed that both recombinant proenzymes have stable purified proteins that are biologically active and exhibit a similar anti-tumoral effect compared to PRP. In fact, cell viability assays suggest that the recombinant proenzymes may even have a stronger anti-tumor effect than pancreatic proenzymes from bovine origin.
Dr Julian Kenyon, Propanc's Chief Scientific Officer, praised the work done by Aitor González in producing recombinant proenzymes.